US Senate panel votes to outlaw ‘pay-for-delay’ deals

Home/Policies & Legislation | Posted 16/11/2009 post-comment0 Post your comment

The US Senate Judiciary Committee has voted 12-7 in favour of legislation to outlaw deals agreed between branded drugmakers and generics firms to delay the entry of generic competitors to the market.

picture18

The Preserve Access to Affordable Generics Act (S.369), which was introduced by Democratic Senator Herb Kohl with cross-party support, would only permit such pay-for-delay deals if the companies involved could provide “clear and convincing evidence” that an agreement would promote competition. The original bill – introduced by Senator Kohl in February 2009 – sought to ban such deals outright, but the version approved on 15 October 2009 eases this slightly by stating that the presumption is that they are illegal. This is also the view that the Justice Department now takes of such arrangements.

Panel members who voted against the bill say the level of proof it would require to show the deals promote competition is too high, and that it could have the effect of discouraging agreements that do just that. On the other hand, some of the bill’s supporters are unhappy that its provisions have not been rolled into the US Senate health reform legislation, which is set for a floor vote fairly soon, possibly in the week beginning 26 October 2009, after it has received a financial scoring from the US Congressional Budget Office (CBO).

Nevertheless, the vote was welcomed by Mr Jon Leibowitz, Chairman of the Federal Trade Commission, who has condemned pay-for-delay deals as anti-consumer and has sought to have a number of them stopped by the courts. He estimates that banning the deals would save consumers at least US$3.5 billion (Euros 2.36 billion) a year, and also provide significant cost-savings for the federal government, which pays around a third of all prescription drug costs.

Following the Judiciary panel vote, Commissioner Leibowitz said the US Senate Judiciary Committee “clearly recognises the very real danger that these sweetheart deals pose to Americans struggling to pay their medical bills. Consumers must wait, sometimes years, for far less expensive generic drugs when branded pharmaceutical companies pay off their generic competitors to stay out of the market”.

However, Ms Kathleen Jaeger, Chief Executive of the Generic Pharmaceutical Association said it was deeply disappointing that the approved version of S.369 does not include a CBO score, which is needed to determine whether the bill could potentially have the unintended effect of benefitting the brand industry and keeping generics from getting to market in a timely manner.

“It simply makes sound fiscal sense to ensure that members voting on the legislation have a good understanding of its economic impact”, said Ms Jaeger. “Over the years, generic manufacturers have undertaken patent challenges that have ended in pro-competitive, pro-consumer settlements, generating tens of billions of dollars in savings for American consumers. Yet, this bill would result in a de facto prohibition on patent settlements – a terrible result for consumers, businesses and the healthcare system”.

The debate has overlooked the fact that settlements that successfully bring patent litigation to an end typically result in the early and predictable introduction of generic competition, she added.

“Without the ability to settle litigation, generic companies are far less likely to challenge brand patents to the detriment of the healthcare system and consumers. That’s why the current system of a case-by-case review by the federal government, to ensure that pro-consumers settlements are not blocked, benefits consumers over brand companies,” said Ms Jaeger.

Reference:
US Senate panel votes to outlaw ‘pay for delay’ deals. PharmaTimes. 2009 Oct 16.

Source: PharmaTimes

comment icon Comments (0)
Post your comment
Related content
Generic ‘skinny’ labelling under threat in the US
Label prescription drugs
Home/Policies & Legislation Posted 05/11/2021
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010